Current Cancer Therapy Reviews

Editor-in-Chief:

Kurt S. Zaenker
Institute of Immunology and Experimental Oncology
Witten/Herdecke University
Stockumerstraße 10, 58448 Witten
Germany

Back

Become EABM
Become Reviewer

Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy

Volume:2   Issue: 2
Pp: 101-113
Yulia Tabakin-Fix, Inbal Azran-Shaish, Yana Schavinsky-Khrapunsky, Rachel Chamias, Lilach Gohari, Mahmoud Huleihel, Min Li-Weber and Mordechai Aboud
DOI: 10.2174/157339406776872843

Epigenetic Therapies of Cancer

Volume:2   Issue: 2
Pp: 127-135
Yasmin Bootwala and Debdutta Bandyopadhyay
DOI: 10.2174/157339406776872816

Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk

Volume:2   Issue: 2
Pp: 137-155
Tessa M. Bosch, Irma Meijerman, Jos H. Beijnen and Jan H.M. Schellens
DOI: 10.2174/157339406776872825

The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment

Volume:2   Issue: 2
Pp: 157-167
Kai Breuhahn, Tanja Nussbaum, Stephan Singer and Peter Schirmacher
DOI: 10.2174/157339406776872861

Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies

Volume:2   Issue: 2
Pp: 169-183
Laurence Catley and Kenneth C. Anderson
DOI: 10.2174/157339406776872807